Specific targeting of human integrin αvβ3 with 111in-labeled abegrin™ in nude mouse models

Molecular Imaging and Biology

Volumn 13, Issue 1, 2011, Pages 112-120

  Liu, Zhaofei ^a   Jia, Bing ^a   Zhao, Huiyun ^a   Chen, Xiaoyuan ^b,c   Wang, Fan ^a  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

111In; Abegrin ; Imaging; Integrin v 3; Tumor

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ETARACIZUMAB; ETARACIZUMAB 1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID IN 111; FLUORESCEIN ISOTHIOCYANATE; GADOTERIC ACID; INDIUM 111; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG TUMOR LEVEL; FEMALE; GLIOBLASTOMA; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RADIOISOTOPE DISTRIBUTION;

ANIMALS; ANTIBODIES, MONOCLONAL; CELL LINE, TUMOR; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; INDIUM RADIOISOTOPES; INTEGRIN ALPHAVBETA3; MICE; MICE, NUDE; MODELS, ANIMAL; TISSUE DISTRIBUTION;

MUS MUSCULUS;

EID: 79551598150     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-010-0302-4     Document Type: Article

References (39)

1. JA Eble J Haier 2006 Integrins in cancer treatment Curr Cancer Drug Targets 6 89 105 1:CAS:528:DC%2BD28XislSmsLk%3D 10.2174/156800906776056518 16529540
2. FG Giancotti E Ruoslahti 1999 Integrin signaling Science 285 1028 1:CAS:528:DyaK1MXlt1Gns7o%3D 10.1126/science.285.5430.1028 10446041
3. RO Hynes 1992 Integrins: versatility, modulation, and signaling in cell adhesion Cell 69 11 25 1:CAS:528:DyaK38XitFWmtrg%3D 10.1016/0092-8674(92)90115-S 1555235
4. RE Seftor EA Seftor KR Gehlsen WG Stetler-Stevenson PD Brown E Ruoslahti MJ Hendrix 1992 Role of the alpha v beta 3 integrin in human melanoma cell invasion Proc Natl Acad Sci U S A 89 1557 1561 1:CAS:528:DyaK38XhslWhu74%3D 10.1073/pnas.89.5.1557 1371877
5. BP Eliceiri DA Cheresh 1999 The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development J Clin Invest 103 1227 1230 1:CAS:528:DyaK1MXivFansrs%3D 10.1172/JCI6869 10225964
6. CC Kumar 2003 Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis Curr Drug Targets 4 123 131 1:CAS:528:DC%2BD3sXovFShug%3D%3D 10.2174/1389450033346830 12558065
7. PC Brooks RA Clark DA Cheresh 1994 Requirement of vascular integrin alpha v beta 3 for angiogenesis Science 264 569 571 1:CAS:528:DyaK2cXjt1Sis7w%3D 10.1126/science.7512751 7512751
8. A Veeravagu Z Liu G Niu K Chen B Jia W Cai C Jin AR Hsu AJ Connolly V Tse, et al. 2008 Integrin alphavbeta3-targeted radioimmunotherapy of glioblastoma multiforme Clin Cancer Res 14 7330 7339 1:CAS:528: DC%2BD1cXhtlylur%2FM 10.1158/1078-0432.CCR-08-0797 19010848
9. J Shi B Jia Z Liu Z Yang Z Yu K Chen X Chen S Liu F Wang 2008 99mTc-labeled bombesin(7-14)NH2 with favorable properties for SPECT imaging of colon cancer Bioconjug Chem 19 1170 1178 1:CAS:528:DC%2BD1cXmtFWhu70%3D 10.1021/bc700471z 18491928
10. Z Liu F Wang X Chen 2008 Integrin alpha v beta 3-targeted cancer therapy Drug Development Research 69 329 339 1:CAS:528:DC%2BD1MXhtl2hug%3D%3D 10.1002/ddr.20265 20628538
11. AJ Beer AL Grosu J Carlsen A Kolk M Sarbia I Stangier P Watzlowik HJ Wester R Haubner M Schwaiger 2007 [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck Clin Cancer Res 13 6610 6616 1:CAS:528:DC%2BD2sXhtlSmu7nO 10.1158/1078-0432.CCR-07-0528 18006761
12. AJ Beer R Haubner I Wolf M Goebel S Luderschmidt M Niemeyer AL Grosu MJ Martinez HJ Wester WA Weber, et al. 2006 PET-based human dosimetry of 18F-galacto-RGD, a new radiotracer for imaging alpha v beta3 expression J Nucl Med 47 763 769 1:CAS:528:DC%2BD28XltFaiurw%3D 16644745
13. MS Morrison SA Ricketts J Barnett A Cuthbertson J Tessier SR Wedge 2009 Use of a novel Arg-Gly-Asp radioligand, 18F-AH111585, to determine changes in tumor vascularity after antitumor therapy J Nucl Med 50 116 122 1:CAS:528:DC%2BD1MXhvFCjt7s%3D 10.2967/jnumed.108.056077 19091899
14. Z Liu G Niu J Shi S Liu F Wang S Liu X Chen 2009 (68)Ga-labeled cyclic RGD dimers with Gly(3) and PEG (4) linkers: promising agents for tumor integrin alpha (v)beta (3) PET imaging Eur J Nucl Med Mol Imaging 36 947 957 1:CAS:528:DC%2BD1MXls1yjsL0%3D 10.1007/s00259-008-1045-1 19159928
15. GC Tucker 2006 Integrins: molecular targets in cancer therapy Curr Oncol Rep 8 96 103 1:CAS:528:DC%2BD28Xis1yiu70%3D 10.1007/s11912-006-0043-3 16507218
16. JC Gutheil TN Campbell PR Pierce JD Watkins WD Huse DJ Bodkin DA Cheresh 2000 Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3 Clin Cancer Res 6 3056 3061 1:CAS:528:DC%2BD3cXmsVOmsbo%3D 10955784
17. H Wu G Beuerlein Y Nie H Smith BA Lee M Hensler WD Huse JD Watkins 1998 Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb Proc Natl Acad Sci USA 95 6037 1:CAS:528:DyaK1cXjtlKgsro%3D 10.1073/pnas.95.11.6037 9600913
18. W Cai X Chen 2006 Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism Anticancer Agents Med Chem 6 407 428 1:CAS:528: DC%2BD28Xos1Gqt7w%3D 10.2174/187152006778226530 17017851
19. C Delbaldo E Raymond K Vera L Hammershaimb K Kaucic S Lozahic M Marty S Faivre 2008 Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors Invest New Drugs 26 35 43 1:CAS:528: DC%2BD1cXlt1aqtg%3D%3D 10.1007/s10637-007-9077-0 17876527
20. JA Posey MB Khazaeli A DelGrosso MN Saleh CY Lin W Huse AF LoBuglio 2001 A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer Cancer Biother Radiopharm 16 125 132 1:CAS:528:DC%2BD3MXktF2hu7k%3D 10.1089/108497801300189218 11385959
21. W Cai Y Wu K Chen Q Cao DA Tice X Chen 2006 In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3 Cancer Res 66 9673 9681 1:CAS:528: DC%2BD28XhtVams73J 10.1158/0008-5472.CAN-06-1480 17018625
22. MG Scheer TH Stollman OC Boerman K Verrijp FC Sweep WP Leenders TJ Ruers WJ Oyen 2008 Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression Eur J Cancer 44 1835 1840 1:CAS:528:DC%2BD1cXhtVamt7rL 10.1016/j.ejca.2008.05.026 18632262
23. A Iagaru SS Gambhir ML Goris 2008 90Y-ibritumomab therapy in refractory non-Hodgkin's lymphoma: observations from 111In-ibritumomab pretreatment imaging J Nucl Med 49 1809 1812 10.2967/jnumed.108.052928 18927323
24. N Pandit-Taskar JA O'Donoghue MJ Morris EA Wills LH Schwartz M Gonen HI Scher SM Larson CR Divgi 2008 Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy J Nucl Med 49 1066 1074 10.2967/jnumed.107.049502 18552139
25. TM Behr M Behe B Wormann 2001 Trastuzumab and breast cancer N Engl J Med 345 995 996 1:CAS:528:DC%2BD3MXntlehtbk%3D 10.1056/NEJM200109273451312 11575295
26. A Banning A Kipp S Schmitmeier M Lowinger S Florian S Krehl S Thalmann R Thierbach P Steinberg R Brigelius-Flohe 2008 Glutathione Peroxidase 2 Inhibits Cyclooxygenase-2-Mediated Migration and Invasion of HT-29 Adenocarcinoma Cells but Supports Their Growth as Tumors in Nude Mice Cancer Res 68 9746 9753 1:CAS:528:DC%2BD1cXhsVegtbvF 10.1158/0008-5472.CAN-08-1321 19047153
27. Z Liu Z Yu W He S Ma L Sun F Wang 2009 In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model Cancer Biother Radiopharm 24 15 24 10.1089/cbr.2008.0537 19216631
28. W Shao S Zhao Z Liu J Zhang S Ma JD Sato P Zhang M Tong J Han Y Wang, et al. 2006 Inhibition of human tumor xenograft growth in nude mice by a conjugate of monoclonal antibody LA22 to epidermal growth factor receptor with anti-tumor antibiotics mitomycin C Biochem Biophys Res Commun 349 816 824 1:CAS:528:DC%2BD28Xps1Ogt70%3D 10.1016/j.bbrc.2006.08.114 16950201
29. Z Liu Y Yan FT Chin F Wang X Chen 2009 Dual Integrin and Gastrin-Releasing Peptide Receptor Targeted Tumor Imaging Using (18)F-labeled PEGylated RGD-Bombesin Heterodimer (18)F-FB-PEG(3)-Glu-RGD-BBN J Med Chem 52 425 432 1:CAS:528:DC%2BD1MXnt1Kg 10.1021/jm801285t 19113865
30. Q He Z Liu B Jia X Li J Shi J Zhang F Lan Z Yang Y Liu L Shen, et al. 2008 In vivo gamma imaging of the secondary tumors of transplanted human fetal striatum neural stem cells-derived primary tumor cells NeuroReport 19 1009 1014 10.1097/WNR.0b013e328303c020 18580570
31. H Maeda J Fang T Inutsuka Y Kitamoto 2003 Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications Int Immunopharmacol 3 319 328 1:CAS:528:DC%2BD3sXhvFGktLc%3D 10.1016/S1567-5769(02)00271-0 12639809
32. CA Boswell X Sun W Niu GR Weisman EH Wong AL Rheingold CJ Anderson 2004 Comparative in vivo stability of copper-64-labeled cross-bridged and conventional tetraazamacrocyclic complexes J Med Chem 47 1465 1474 1:CAS:528:DC%2BD2cXhtFagtLw%3D 10.1021/jm030383m 14998334
33. Z Liu Z Li Q Cao S Liu F Wang X Chen 2009 Small-animal PET of tumors with 64Cu-labeled RGD-bombesin heterodimer J Nucl Med 50 1168 1177 1:CAS:528:DC%2BD1MXpsV2gsbY%3D 10.2967/jnumed.108.061739 19525469
34. JE Sprague Y Peng X Sun GR Weisman EH Wong S Achilefu CJ Anderson 2004 Preparation and biological evaluation of copper-64-labeled tyr3-octreotate using a cross-bridged macrocyclic chelator Clin Cancer Res 10 8674 8682 1:CAS:528:DC%2BD2cXhtFGjsL7F 10.1158/1078-0432.CCR-04-1084 15623652
35. AF Prasanphanich PK Nanda TL Rold L Ma MR Lewis JC Garrison TJ Hoffman GL Sieckman SD Figueroa CJ Smith 2007 [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues Proc Natl Acad Sci U S A 104 12462 12467 1:CAS:528:DC%2BD2sXos1ehtLw%3D 10.1073/pnas.0705347104 17626788
36. CL Gladson 1996 Expression of integrin alpha v beta 3 in small blood vessels of glioblastoma tumors J Neuropathol Exp Neurol 55 1143 1149 1:CAS:528:DyaK28XnsVakur8%3D 10.1097/00005072-199611000-00005 8939197
37. H Maeda 2001 The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting Adv Enzyme Regul 41 189 207 1:CAS:528:DC%2BD3MXmtlekt7k%3D 10.1016/S0065- 2571(00)00013-3 11384745
38. HJ Aerts L Dubois L Perk P Vermaelen GA van Dongen BG Wouters P Lambin 2009 Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET J Nucl Med 50 123 131 1:CAS:528:DC%2BD1MXhvFCjt7g%3D 10.2967/jnumed.108.054312 19091906
39. K McLarty B Cornelissen DA Scollard SJ Done K Chun RM Reilly 2009 Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts Eur J Nucl Med Mol Imaging 36 81 93 1:CAS:528: DC%2BD1cXhsVGqurzK 10.1007/s00259-008-0923-x 18712381